News

Abbott Laboratories will pay $385 million to resolve claims tied to an investigation of contamination at a baby formula factory in Sturgis, Michigan, the largest in the country, which led to the supply shortages in 2022. Problems at the facility prompted a lawsuit by the Justice Department and recall of powdered infant formula at the facility. The recall covered several infant formula brands, including Similac, and squeezed inventory that had already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.

Some federal prosecutors believed there was enough evidence to bring criminal charges, but Justice Department leadership opted for a civil settlement.

FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...

Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

The bulk settlement relates to the Gill lawsuit, in which a Missouri jury ordered the company to pay $495 million in damages after determining it failed to warn that its formula for preterm infants increased the risk for a bowel disease.

Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday.

These stocks can help you withstand (almost) any storm.

AllianceBernstein (NYSE:AB) reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth. Adjusted earnin

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Prosecutors have declined to charge businesses in a number of recent cases—despite believing that senior employees were involved in wrongdoing.

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.

Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.

US benchmark equity indexes were lower intraday amid a sell-off in certain chip-related stocks as in

The S&P 500 and Nasdaq Composite were down in late-morning trading Thursday, while the Dow Jones Ind

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara

Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r

Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.

US equity markets were mostly tracking in the red before the opening bell Thursday as traders await

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.

Abbott Laboratories is scheduled to report its second-quarter results in July, and analysts expect a single-digit earnings rise.

About 50 million Americans aren’t getting screened for colon cancer at a time when colon-cancer rates are rising.

The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. The rise of the Make America Healthy Again movement, with its vaccine skepticism and adversarial stance toward drugmakers, has hung over biotech since Robert F. Kennedy Jr. took over at the Department of Health and Human Services.